OrthoPediatrics (NASDAQ:KIDS) Given New $30.00 Price Target at Needham & Company LLC

OrthoPediatrics (NASDAQ:KIDS) had its price objective increased by research analysts at Needham & Company LLC from $26.00 to $30.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 68.63% from the company’s current price.

A number of other research analysts have also commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Canaccord Genuity Group started coverage on OrthoPediatrics in a report on Wednesday, December 10th. They issued a “buy” rating and a $24.00 price target on the stock. Wall Street Zen lowered OrthoPediatrics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Finally, TD Cowen upgraded shares of OrthoPediatrics to a “strong-buy” rating in a research report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, OrthoPediatrics presently has an average rating of “Moderate Buy” and an average price target of $24.44.

OrthoPediatrics Price Performance

Shares of KIDS stock opened at $17.79 on Friday. OrthoPediatrics has a 52 week low of $15.28 and a 52 week high of $26.40. The stock has a market capitalization of $446.12 million, a PE ratio of -9.12 and a beta of 1.12. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.52 and a current ratio of 7.40. The stock’s fifty day moving average is $17.60 and its 200-day moving average is $18.15.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. The firm had revenue of $61.61 million for the quarter, compared to analyst estimates of $61.27 million. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. Equities research analysts expect that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its holdings in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the period. Caption Management LLC bought a new position in OrthoPediatrics during the third quarter worth about $54,000. BNP Paribas Financial Markets increased its holdings in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares in the last quarter. Finally, State of Wyoming raised its position in shares of OrthoPediatrics by 189.7% during the fourth quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after purchasing an additional 4,467 shares during the period. Institutional investors and hedge funds own 69.05% of the company’s stock.

More OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Q4 beat on EPS and revenue — OrthoPediatrics reported a loss of ($0.26) per share, beating the consensus loss of ($0.37), and delivered $61.61M in revenue, slightly above estimates; the beat on both EPS and revenue likely supported the stock move. MarketBeat: Q4 release
• Positive Sentiment: Company reiterated FY2026 revenue target of $262M–$266M and flagged an accelerating “product innovation super-cycle” — management kept its revenue range roughly in line with street expectations and emphasized product momentum, which supports growth expectations. Seeking Alpha: Guidance & product cycle
• Positive Sentiment: Earnings call highlighted strong revenue growth and encouraging operational commentary — management commentary on the call and the published transcript supported the view that commercial execution and product rollouts are picking up. Yahoo Finance: Q4 highlights Seeking Alpha: Call transcript
• Neutral Sentiment: Management will participate in upcoming investor conferences — presence at conferences increases investor access and visibility but is routine; it may help sustain interest if follow-up data or targets are presented. GlobeNewswire: Conference participation
• Negative Sentiment: Company remains unprofitable with negative margins and return on equity — despite the beats, OrthoPediatrics reported a negative net margin (~20%) and negative ROE; analysts still model a loss for the year, which limits valuation expansion until sustained profitability is shown. Zacks: Q4 loss & metrics

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.